Determinants of invasiveness and ability to cause invasive pneumococcal disease, pneumonia and acute otitis media of different serotypes of Streptococcus pneumoniae

Journal of Preventive Medicine and Hygiene

Volumn 52, Issue 2, 2011, Pages 47-54

  Zancoli, Marta ^a   Canepa, P ^a   Ceravolo, A ^a   Parodi, V ^a   Ansaldi, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Invasive pneumococcal disease; Pneumococcal virulence factors; Streptococcus pneumoniae

Indexed keywords

BINDING PROTEIN; CHOLINE; HYALURONIDASE; LIPOPROTEIN; PNEUMOLYSIN; SIALIDASE; VIRULENCE FACTOR;

ACUTE OTITIS MEDIA; BACTERIAL CELL WALL; BACTERIAL MEMBRANE; BACTERIUM PILUS; HUMAN; NONHUMAN; REVIEW; SEROTYPE; SPECIES INVASION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ACUTE DISEASE; AGED; CHILD; HUMANS; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 79961065911     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005;5:83-93.
2. Konradsen HB, Kaltoft MS. Invasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes and resistance. Clin Diagn Lab Immunol 2002;9:358-65.
3. Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002;2:25-32.
4. McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003;9:424-30. (Pubitemid 36460076)
5. Pilishvili T, Lexau C, Farley MM, et al. Active Bacterial Core Surveillance Emerging Infections Programme Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;1;201:32-41.
6. Coffey TJ, Enright MC, Daniels M, et al. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae. Mol Microbiol 1998;27:73-83.
7. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007;26:468-72.
8. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by non-vaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 200725;297:1784-92.
9. Black S, France EK, Isaacman D, et al. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007;26:771-7.
10. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 20105;7(10). pii: e1000348.
11. Ansaldi F, De Florentiis D, Canepa P, et al. Serotype replacement in Streptococcus pneumoniae after conjugate vaccine introduction: impact, doubts and perspective for new vaccines. Reviews in Medical Microbiology 2010;21:56-64.
12. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009;6:e1000081.
13. Sandgren A, Sjostrom K, Olsson-Liljequist B, et al. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Infect Dis 2004;189:785-96.
14. Kadioglu A, Weiser JN, Paton JC, et al. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008;6:288-301.
15. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev 2001;65:187-207.
16. Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010;51:692-9.
17. Gillespie SH, Balakrishnan I. Pathogenesis of pneumococcal infection. Med Microbiol 2000;49:1057-67.
18. Weinberger DM, Trzciński K, Lu YJ, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 2009;5:e1000476.
19. Engelhard D, Pomeranz S, Gallily R, et al. Serotype-related differences in inflammatory response to Streptococcus pneumoniae in experimental meningitis. J Infect Dis 1997;175:979-82. (Pubitemid 27142982)
20. Fernebro J, Andersson I, Sublett J, et al. Capsular expression in Streptococcus pneumoniae negatively affects spontaneous and antibiotic-induced lysis and contributes to antibiotic tolerance. J Infect Dis 2004;189:328-38.
21. Barocchi MA, Ries J, Zogaj X, et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A 2006;103:2857-62.
22. Basset A, Trzcinski K, Hermos C, et al. Association of the pneumococcal pilus with certain capsular serotypes but not with increased virulence. J Clin Microbiol 2007;45:1684-9.
23. García JL, Sánchez-Beato AR, Medrano FJ. Versatility of choline-binding domain. Microb Drug Resist 1998;4:25-36.
24. Abeyta M, Hardy GG, Yother J. Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun 2003;71:218-25.
25. Jounblat R, Kadioglu A, Mitchell TJ, et al. Pneumococcal behavior and host responses during bronchopneumonia are affected differently by the cytolytic and complement-activating activities of pneumolysin. Infect Immun 2003;71:1813-9.
26. Tuomanen E, Tomasz A. Mechanism of phenotypic tolerance of nongrowing pneumococci to beta-lactam antibiotics. Scand J Infect Dis Suppl 1990;74:102-12.
27. Bergmann S, Hammerschmidt S. Versatility of pneumococcal surface proteins. Microbiology 2006;152(Pt2):295-303.
28. Brown JS, Ogunniyi AD, Woodrow MC, et al. Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection. Infect Immun 2001;69:6702-6. (Pubitemid 32995427)
29. Paterson GK, Mitchell TJ. The role of Streptococcus pneumoniae sortase A in colonisation and pathogenesis. Microbes Infect 2006;8:145-53.
30. Kadioglu A, Coward W, Colston MJ, et al. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun 2004;72:2689-97.
31. Orihuela CJ, Gao G, Francis KP, et al. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J Infect Dis 2004;190:1661-9.
32. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A 2003;100:1966-71.
33. King SJ, Hippe KR, Gould JM, et al. Phase variable desialylation of host proteins that bind to Streptococcus pneumoniae in vivo and protect the airway. Phase variable desialylation of host proteins that bind to Streptococcus pneumoniae in vivo and protect the airway. Mol Microbiol 2004;54:159-71. (Pubitemid 39315166)
34. Manco S, Hernon F, Yesilkaya H, et al. Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis. Infect Immun 2006;74:4014-20.
35. Pettigrew MM, Fennie KP, York MP, et al. Variation in the presence of neuraminidase genes among Streptococcus pneumoniae isolates with identical sequence types. Infect Immun 2006;74:3360-5. (Pubitemid 43794525)
36. Volkova MO, Kostiukova NN, Kvetnaia AS. The role of hyaluronidase in the occurrence of a generalized pneumococcal infection. Zh Mikrobiol Epidemiol Immunobiol 1994;(Suppl 1):118-22.
37. Martens P, Worm SW, Lundgren B, et al. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis 2004;4:21.
38. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009;6:e1000081.
39. Takala AK, Vuopio-Varkila J, Tarkka E, et al. Subtyping of common pediatric pneumococcal serotypes from invasive disease and pharyngeal carriage in Finland. J Infect Dis 1996;173:128-35.
40. Brueggemann AB, Griffiths DT, Meats E, et al. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 2003;187:1424-32.
41. Brueggemann AB, Peto TE, Crook DW, et al. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004;190:1203-11. (Pubitemid 39287745)
42. Hanage WP, Kaijalainen TH, Syrjänen RK, et al. Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect Immun 2005;73:431-5.
43. Sjöström K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 200615;42:451-9.
44. Gilbert K, Fine MJ. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Semin Respir Infect 1994;9:140-52.
45. Henriques B, Kalin M, Ortqvist A, et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000;182:833-9.
46. Rückinger S, von Kries R, Siedler A, et al. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J 2009;28:118-22.
47. Alanee SR, McGee L, Jackson D, et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 2007;45:46-51.
48. Yildirim I, Hanage WP, Lipsitch M, et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2010;29:283-8.
49. Centers for Disease Control and Prevention (CDC). Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine-United States, 1997-2006. MMWR Morb Mortal Wkly Rep 2009;58:1-4.
50. Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002;2:25-32.
51. http://www.who.int/vaccines/en/pneumococcus.shtml
52. Hausdorff WP, Dagan R. Serotypes and pathogens in paediatric pneumonia. Vaccine 2008;26(Suppl 2):B19-23.
53. Camou T, Palacio R, Di Fabio JL, et al. Invasive pneumococcal diseases in Uruguayan children: comparison between serotype distribution and conjugate vaccine formulations. Vaccine 200316;21:2093-6.
54. Dagan R, Givon-Lavi N, Bar-Ziv J The association of nasopharyngeal (NP) S. pneumoniae (Pnc) serotypes with community-acquired alveolar pneumonia (CAAP) determined by WHO standardization of interpretation of chest radiographs in children (WHO-SICR) 2004. Abstr. 44. Fourth Int. Symp. Pneumococci Pneumococcal Dis., Helsinki, Finland, 9 to 13 May 2004.
55. Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010;51:692-9.
56. Resti M, Moriondo M, Cortimiglia M, et al. Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-time polymerase chain reaction using blood samples. Clin Infect Dis 2010;51:1042-9.
57. Yu J, Salamon D, Marcon M, et al. Pneumococcal serotypes causing pneumonia with pleural effusion in pediatric patients. J Clin Microbiol 2011;49:534-8.
58. Kilpi T, Herva E, Kaijalainen T, et al. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J 2001;20:654-62.
59. del Castillo F, Garcia-Perea A, Baquero-Artigao F. Bacteriology of acute otitis media in Spain: a prospective study based on tympanocentesis. Pediatr Infect Dis J 1996;15:541-3.
60. Syrjänen RK, Kilpi TM, Kaijalainen TH, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Finnish children younger than 2 years old. J Infect Dis 2001;184:451-9.
61. Rosenfeld RM, Bluestone CD. Evidence-based otitis media. Hamilton, Ontario: B.C. Decker 1999.
62. Ghaffar F, Friedland IR, McCracken GH, Jr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J 1999;18:638-46.
63. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-21.
64. Hanage WP, Auranen K, Syrjänen R, et al. Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines. Infect Immun 2004;72:76-81.
65. Shouval DS, Greenberg D, Givon-Lavi N, et al. Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J 2006;25:602-7.
66. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46.
67. Nahm MH, Lin J, Finkelstein JA, et al. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis 2009;199:320-5.
68. McIntosh ED, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines 2011;10:109-29.
69. Brueggemann AB, Pai R, Crook DW, et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007;3:e168.